Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach.
Toby M MaherKevin K BrownSteven CunninghamEmily M DeBoerRobin DeterdingElizabeth K FiorinoMatthias GrieseNicolaus SchwerkDavid WarburtonLisa R YoungMartina GahlemannFlorian VossChristian Stocknull nullPublished in: Pediatric pulmonology (2024)
These findings, together with the safety data from the InPedILD trial, support the use of nintedanib in children and adolescents with fibrosing ILDs.